Cancer BiologybioRxivPreprint
The STAMP inhibitor asciminib is a new treatment option for ABL-rearranged ALL revealing a novel role for the 5' fusion partner in determining drug response
Laura N Eadie, Daniel P. McDougal, Elias Lagonik…·Deborah L. White
This study shows asciminib effectively treats NUP214::ABL1 ALL in preclinical models by inhibiting ABL1 kinase and improving survival.
DOI 10.1101/2025.05.06.652078